State of the Science Summit on GI Malignancies | Conference

Dr. Iqbal on the Biggest Advance in the Treatment of Neuroendocrine Tumors

November 6th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).

Dr. Barzi on Available and Emerging Neoadjuvant Approaches in Pancreatic Cancer

November 6th 2018

Afsaneh Barzi, MD, assistant professor of clinical medicine, Norris Comprehensive Cancer Center, University of Southern California, discusses available and emerging neoadjuvant strategies for the treatment of patients with nonmetastatic pancreatic cancer.

Treatment Updates Move Neuroendocrine Tumor Paradigm Forward

October 31st 2018

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

Role of Immunotherapy May Expand in Gastric/GEJ Cancers

October 31st 2018

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

Dr. Lenz on the Benefit of Regorafenib in CRC

October 26th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

October 23rd 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Optimal Sequencing Key Next Step for HCC Paradigm

October 18th 2018

Anthony B. El-Khoueiry, MD, discusses the promising hepatocellular carcinoma treatment paradigm.

Expert Discusses Emerging Treatments in Early Pancreatic Cancer

October 17th 2018

Afsaneh Barzi, MD, discusses updates in the treatment of patients with pancreatic cancer, as well as the importance of genetic testing.

Lenz Highlights Ongoing Advances in mCRC

October 17th 2018

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

Dr. El-Khoueiry Discusses Recent Combination Data in HCC

October 17th 2018

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma.

Dr. Iqbal on Treatment Options for Patients With Neuroendocrine Tumors

October 17th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses treatment options for patients with neuroendocrine tumors (NETs).

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

Dr. Lenz on the Changing Landscape of Metastatic Colorectal Cancer

October 16th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

Dr. Barzi on Surgical Advances in Pancreatic Cancer

October 12th 2018

Afsaneh Barzi, MD, assistant professor of clinical medicine, USC Norris Comprehensive Cancer Center, discusses surgical advances in the treatment of patients with pancreatic cancer.

Amid Success, Immunotherapy Faces Challenges in GI Malignancies

June 8th 2018

Gregory L. Beatty, MD, PhD, shares his insight on the challenges with sequencing immunotherapies in light of recent advancements in gastrointestinal malignancies.

Surgery Remains Vital in Hepatobiliary Neoplasms

June 8th 2018

Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care

May 23rd 2018

Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

Collisson Covers Cholangiocarcinoma and Colon Cancer Challenges

May 21st 2018

Eric A. Collisson, MD, speaks to the challenges and emerging advancements in cholangiocarcinoma and colon cancer.

Expert Calls for Smarter Clinical Trials in Pancreatic Neoplasms

May 18th 2018

Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.

Dr. Collisson on the Difficulty of Diagnosing Cholangiocarcinoma

May 3rd 2018

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the difficulty of diagnosing cholangiocarinoma.